[Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid]
- PMID:8200147
[Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease--the effect of supplement therapy to gastric acid]
Abstract
Since an oral regimen of levodopa has been instituted for treatment of Parkinson's disease, its absorption and metabolism has been well demonstrated. However, its chemical characteristics of high solubility in acid solution and low solubility in water have not been well known. We paid attention to this characteristic and studied the relationship between its absorption and gastric acid secretion in 38 patients with Parkinson's disease who became refractory to therapy of levodopa. We measured the pH and amount of collected fasting gastric juice. Gastric acid secretion was decreased in 22 patients (58%). In ten of these 22 patients, 30 ml of lemon juice was prescribed in every administration of levodopa as a supplement to gastric acid for two weeks. Increases of L-dopa concentration after 60 min. and 180 min. were observed after lemon juice supplement therapy. Among the Parkinson symptoms, rigidity, akinesia, and small step gait were improved in every case except one patient who showed decrease of L-dopa concentration at 180 minutes. However, improvement of tremor was less remarkable. We consider this supplement therapy to gastric acid is one of the effective and useful methods in the management of Parkinson's disease.
Similar articles
- Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I.Kurlan R, et al.Neurology. 1988 Mar;38(3):419-21. doi: 10.1212/wnl.38.3.419.Neurology. 1988.PMID:3126408
- Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.Djaldetti R, Ziv I, Melamed E.Djaldetti R, et al.Isr J Med Sci. 1996 Dec;32(12):1224-7.Isr J Med Sci. 1996.PMID:9007159Review.
- Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, Takahashi O.Doi H, et al.J Neurol Sci. 2012 Aug 15;319(1-2):86-8. doi: 10.1016/j.jns.2012.05.010. Epub 2012 May 25.J Neurol Sci. 2012.PMID:22632782
- Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.Kumar R, Hauser RA, Mostillo J, Dronamraju N, Graf A, Merschhemke M, Kenney C.Kumar R, et al.Int J Neurosci. 2016;126(1):20-4. doi: 10.3109/00207454.2013.841685. Epub 2015 Aug 18.Int J Neurosci. 2016.PMID:24007304Clinical Trial.
- Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.LeWitt PA.LeWitt PA.Mov Disord. 2015 Jan;30(1):64-72. doi: 10.1002/mds.26082. Epub 2014 Dec 1.Mov Disord. 2015.PMID:25449210Review.
Cited by
- Pretreatment of Ascorbic Acid Inhibits MPTP-Induced Astrocytic Oxidative Stress through Suppressing NF-κB Signaling.Zeng X, Xu K, Wang J, Xu Y, Qu S.Zeng X, et al.Neural Plast. 2020 Nov 17;2020:8872296. doi: 10.1155/2020/8872296. eCollection 2020.Neural Plast. 2020.PMID:33281897Free PMC article.
- Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson's disease.Miyaue N, Yabe H, Nagai M.Miyaue N, et al.Clin Park Relat Disord. 2023 Oct 31;9:100227. doi: 10.1016/j.prdoa.2023.100227. eCollection 2023.Clin Park Relat Disord. 2023.PMID:38021340Free PMC article.
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.Katzenschlager R, et al.J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.J Neurol Neurosurg Psychiatry. 2004.PMID:15548480Free PMC article.Clinical Trial.
MeSH terms
Substances
Related information
LinkOut - more resources
Medical